Improvement of drug safety by the use of lipid-based nanocarriers
- PMID: 22698939
- DOI: 10.1016/j.jconrel.2012.06.002
Improvement of drug safety by the use of lipid-based nanocarriers
Abstract
Drug toxicity is an important factor that contributes significantly to adverse drug events in current healthcare practice. Application of lipid-based nanocarriers in drug formulation is one approach to improve drug safety. Lipid-based delivery systems include micelles, liposomes, solid lipid nanoparticles, nanoemulsions and nanosuspensions. These carriers are generally composed of physiological lipids well tolerated by human body. Delivery of water-insoluble drugs in these formulations increases their solubility and stability in aqueous media and eliminates the need for toxic co-solvents or pH adjustment to solubilize hydrophobic drugs. Association or encapsulation of peptides/proteins within lipid-based carriers protects the labile biologics against enzymatic degradation, hence reducing the therapeutic dose required and risk of dose-dependent toxicity. Most importantly, lipid-based nanocarriers alter the pharmacokinetics and biodistribution of drugs through passive and active targeting, leading to increased drug accumulation at target sites while significantly decreasing non-specific distribution to other tissues. Furthermore, surface modification of these nanocarriers reduces immunogenicity of drug-carrier complexes, imparts stealth by preventing opsonization and removal by phagocytes and minimizes interaction with circulating blood components. In view of heightening attention on drug safety in patient treatment, lipid-based nanocarrier is therefore an important and promising option for formulation of pharmaceutical products to improve treatment safety and efficacy.
Copyright © 2012 Elsevier B.V. All rights reserved.
Similar articles
-
Advances in lipid nanodispersions for parenteral drug delivery and targeting.Adv Drug Deliv Rev. 2008 Mar 17;60(6):757-67. doi: 10.1016/j.addr.2007.10.013. Epub 2007 Nov 6. Adv Drug Deliv Rev. 2008. PMID: 18096269 Review.
-
Nanocarriers for oral drug delivery.J Drug Target. 2013 Jul;21(6):515-27. doi: 10.3109/1061186X.2013.789033. Epub 2013 Apr 26. J Drug Target. 2013. PMID: 23621127 Review.
-
Solid lipid nanoparticles: an oral bioavailability enhancer vehicle.Expert Opin Drug Deliv. 2011 Nov;8(11):1407-24. doi: 10.1517/17425247.2011.604311. Epub 2011 Aug 11. Expert Opin Drug Deliv. 2011. PMID: 21831007 Review.
-
Lipid nanoparticles for improved topical application of drugs for skin diseases.Adv Drug Deliv Rev. 2007 Jul 10;59(6):427-43. doi: 10.1016/j.addr.2007.04.006. Epub 2007 May 3. Adv Drug Deliv Rev. 2007. PMID: 17544165 Review.
-
Recent advances in topical ophthalmic drug delivery with lipid-based nanocarriers.Drug Discov Today. 2013 Mar;18(5-6):290-7. doi: 10.1016/j.drudis.2012.10.005. Epub 2012 Oct 22. Drug Discov Today. 2013. PMID: 23092895 Review.
Cited by
-
Liposomes as Antibiotic Delivery Systems: A Promising Nanotechnological Strategy against Antimicrobial Resistance.Molecules. 2021 Apr 2;26(7):2047. doi: 10.3390/molecules26072047. Molecules. 2021. PMID: 33918529 Free PMC article. Review.
-
The shape/morphology balance: a study of stealth liposomes via fractal analysis and drug encapsulation.Pharm Res. 2013 Sep;30(9):2385-95. doi: 10.1007/s11095-013-1082-8. Epub 2013 Jun 7. Pharm Res. 2013. PMID: 23743657
-
VIP-targeted Cytotoxic Nanomedicine for Breast Cancer.Drug Deliv Transl Res. 2012 Dec 1;2(6):454-62. doi: 10.1007/s13346-012-0107-x. Drug Deliv Transl Res. 2012. PMID: 23336096 Free PMC article.
-
Development of Solid Lipid Nanoparticles for Controlled Amiodarone Delivery.Methods Protoc. 2023 Oct 9;6(5):97. doi: 10.3390/mps6050097. Methods Protoc. 2023. PMID: 37888029 Free PMC article.
-
Orodispersible Films: A Delivery Platform for Solid Lipid Nanoparticles?Pharmaceutics. 2021 Dec 15;13(12):2162. doi: 10.3390/pharmaceutics13122162. Pharmaceutics. 2021. PMID: 34959444 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical